SLC5A2 and type 2 diabetes mellitus: While SGLT2 inhibitors and GLP-1 RAs have demonstrated significant cardiovascular and renal benefits in CKD and T2D populations, network meta-analyses indicate that SGLT2 inhibitors outperform both Finerenone and GLP-1 RAs in reducing renal outcomes and heart failure hospitalizations [34].